About Matt Rightmire

This author has not yet filled in any details.
So far Matt Rightmire has created 56 blog entries.

Avedro Receives FDA Approval for Photrexa Viscous, Photrexa and the KXL System for Corneal Cross-Linking

Avedro, Inc., an ophthalmic pharmaceutical and medical device company, has received approval from the U.S. Food and Drug Administration (FDA) for Photrexa Viscous, Photrexa and the KXL System. Photrexa Viscous and Photrexa are photoenhancers indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus. Avedro’s Photrexa Viscous, Photrexa [...]

By | April 18th, 2016|Dartmouth Innovation, New Hampshire, News|

Mutant Yeast Are Cranking Out Pharma’s Next Superdrug

The offices of Adimab, a biotech company in Lebanon, New Hampshire, smell pleasantly of fresh bread. It’s an olfactory illusion, albeit a welcome one. Nobody is baking anything. The laboratory is lined with beaker after beaker of incubating Saccharomyces cerevisiae—yeast. So, no crusty treats, but instead Adimab is using all that yeast to cure cancer. [...]

By | March 10th, 2016|Dartmouth Innovation, New Hampshire, News|

Adimab Scientists Report the Isolation of Highly Potent Anti-Ebola Virus Antibodies from Recent Zaire Outbreak

Adimab, LLC, a global leader in the discovery of human antibodies, today reported the isolation of a broad panel of neutralizing anti-Ebola virus antibodies from a survivor of the recent Zaire outbreak. The work, published online today in the journal Science, highlights the remarkable speed of Adimab's recently launched single B cell isolation platform, and [...]

By | February 18th, 2016|New Hampshire|

Adimab Announces Technology Transfer Agreement with Merck – Fourth Company to Internalize the Platform

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it has entered into a definitive agreement with Merck, known as MSD outside the United States and Canada, to transfer Adimab’s antibody technology to Merck Research Laboratories for the discovery and optimization of monoclonal and [...]

By | January 12th, 2016|Dartmouth Innovation, News|

Adimab Provides Update on Recent Partnerships and Milestones

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it has entered into definitive agreements with several new companies, as well as expanded partnerships with several of its current partners. In addition, Adimab announced the achievement of technical and development milestones under a number [...]

By | January 11th, 2016|New Hampshire|

Avedro Announces CE Mark Clearance for its Mosaic Advanced Cross‐Linking System and CEO Transition

Avedro, Inc. announced today that it has received CE Mark clearance for its Mosaic System. The Mosaic System has the potential for non‐surgical improvement for low myopia with a procedure called PiXL™ (Photorefractive Intrastromal Cross‐linking). The Mosaic system is now commercially available outside of the United States. Read More

By | December 23rd, 2015|Dartmouth Innovation, News|

Google X Alum Flux Factory Raises $29M Series B

One of Google X’s former moonshots is raising cash as it looks to disrupt the architecture design space with its specialized collaborative data exchange service. Flux Factory, Inc. announced $29 million in Series B funding co-led by Temasek and Surbana Jurong Private Limited. Far East Ventures, DFJ, South Park Ventures, Borealis Ventures, and Obvious Ventures [...]

By | December 21st, 2015|Design & Engineering Software, News|

Adimab Establishes Antibody Discovery Collaborations with MD Anderson and Memorial Sloan Kettering

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced two independent academic collaborations, one with The University of Texas MD Anderson Cancer Center and the other with Memorial Sloan Kettering. In each of these collaborations, Adimab will use its proprietary yeast-based discovery platform to generate [...]

By | December 8th, 2015|News|

Bespoke Bioprocessing Resins

BioPharm International sat down with Kevin Isett, PhD, co-founder and CEO of Avitide, to find out why he thinks the company’s tailored approach to purification resins will change the face of biopharmaceutical separation. The lessons that Kevin Isett learned during his time at Adimab, a therapeutic antibody discovery technology company, were top of mind when [...]

By | December 1st, 2015|Dartmouth Innovation, New Hampshire, News|

Manchester companies make Deloitte Fast 500 list

Two Manchester, NH companies made the list of fastest growing technology businesses. Dyn Inc. and Newforma Inc. were both recognized in Deloitte’s Technology Fast 500, which ranks the fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Dyn, which also made the Deloitte’s Fast 500 two years ago, came in [...]

By | November 16th, 2015|New Hampshire, News|